369 related articles for article (PubMed ID: 25034480)
1. Molecular virology of hepatitis B virus and targets for antiviral intervention.
Glebe D; König A
Intervirology; 2014; 57(3-4):134-40. PubMed ID: 25034480
[TBL] [Abstract][Full Text] [Related]
2. The molecular virology of hepatitis B virus.
Glebe D; Bremer CM
Semin Liver Dis; 2013 May; 33(2):103-12. PubMed ID: 23749666
[TBL] [Abstract][Full Text] [Related]
3. HBV evolution and genetic variability: Impact on prevention, treatment and development of antivirals.
Glebe D; Goldmann N; Lauber C; Seitz S
Antiviral Res; 2021 Feb; 186():104973. PubMed ID: 33166575
[TBL] [Abstract][Full Text] [Related]
4. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets.
Ringelhan M; O'Connor T; Protzer U; Heikenwalder M
J Pathol; 2015 Jan; 235(2):355-67. PubMed ID: 25196558
[TBL] [Abstract][Full Text] [Related]
5. Virological Basis for the Cure of Chronic Hepatitis B.
Hu J; Cheng J; Tang L; Hu Z; Luo Y; Li Y; Zhou T; Chang J; Guo JT
ACS Infect Dis; 2019 May; 5(5):659-674. PubMed ID: 29893548
[TBL] [Abstract][Full Text] [Related]
6. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver.
Dusséaux M; Masse-Ranson G; Darche S; Ahodantin J; Li Y; Fiquet O; Beaumont E; Moreau P; Rivière L; Neuveut C; Soussan P; Roingeard P; Kremsdorf D; Di Santo JP; Strick-Marchand H
Gastroenterology; 2017 Dec; 153(6):1647-1661.e9. PubMed ID: 28851562
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
8. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.
Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV
Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154
[TBL] [Abstract][Full Text] [Related]
9. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
10. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
[TBL] [Abstract][Full Text] [Related]
11. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
Locarnini S; Warner N
Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
[TBL] [Abstract][Full Text] [Related]
12. Molecular virology of hepatitis B virus.
Locarnini S
Semin Liver Dis; 2004; 24 Suppl 1():3-10. PubMed ID: 15192795
[TBL] [Abstract][Full Text] [Related]
13. Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants.
Glebe D; Geipel A
Intervirology; 2014; 57(3-4):225-31. PubMed ID: 25034492
[TBL] [Abstract][Full Text] [Related]
14. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
Coffin CS; Osiowy C; Myers RP; Gill MJ
J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
[TBL] [Abstract][Full Text] [Related]
15. Control and Eradication Strategies of Hepatitis B Virus.
Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
[TBL] [Abstract][Full Text] [Related]
16. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.
Teo CG; Locarnini SA
Antivir Ther; 2010; 15(3 Pt B):445-9. PubMed ID: 20516564
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
Guo JT; Guo H
Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
[TBL] [Abstract][Full Text] [Related]
18. Emerging pipeline drugs for hepatitis B infection.
Cox N; Tillmann H
Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
[TBL] [Abstract][Full Text] [Related]
19. The current status and future directions of hepatitis B antiviral drug discovery.
Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics of HBV infection.
Locarnini S; Zoulim F
Antivir Ther; 2010; 15 Suppl 3():3-14. PubMed ID: 21041899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
